PRODUCT USE IN UNAPPROVED INDICATION

This adverse event was reported 248090 times

These drugs are most commonly taken by patients reporting PRODUCT USE IN UNAPPROVED INDICATION:

# Drug Count
0 DUPILUMAB 44555
1 DICLOFENAC SODIUM 13433
2 PREDNISONE 13253
3 METHOTREXATE SODIUM 10892
4 ACETAMINOPHEN 10364
5 METHOTREXATE 10158
6 GABAPENTIN 7999
7 RITUXIMAB 7961
8 MYCOPHENOLATE MOFETIL HYDROCHLORIDE 7426
9 MYCOPHENOLATE MOFETIL 7406
See all common drugs associated with PRODUCT USE IN UNAPPROVED INDICATION

PRODUCT USE IN UNAPPROVED INDICATION is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 IBUPROFEN, ACETAMINOPHEN 1717 0.6161
1 CAPLACIZUMAB 619 0.3470
2 OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE 612 0.3007
3 GOLIMUMAB 2706 0.2149
4 ERGOCALCIFEROL 6065 0.2040
5 ACETAMINOPHEN, ASPIRIN, AND CAFFEINE 3858 0.1826
6 PSEUDOEPHEDRINE HCL 1792 0.1637
7 DICLOFENAC POTASSIUM TABLETS 1407 0.1623
8 CORTISONE ACETATE 1828 0.1462
9 DICLOFENAC POTASSIUM 1603 0.1450
See all drugs enriched for association with PRODUCT USE IN UNAPPROVED INDICATION

PRODUCT USE IN UNAPPROVED INDICATION is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Interleukin-5 Antagonist [EPC] 1729 2.5131
1 Provitamin D2 Compound [EPC] 6066 0.2039
2 Guanylate Cyclase-C Agonist [EPC] 404 0.1947
3 Interleukin-17A Antagonist [EPC] 4151 0.1113
4 Antiparasitic [EPC] 481 0.1060
5 CD38-directed Cytolytic Antibody [EPC] 611 0.1044
6 Pediculicide [EPC] 490 0.1041
7 Anthelmintic [EPC] 259 0.0891
8 Interleukin-4 Receptor alpha Antagonist [EPC] 44555 0.0859
9 Methylxanthine [EPC] 4938 0.0850
See all drug classes enriched for association with PRODUCT USE IN UNAPPROVED INDICATION